100 years of ibogaine: neurochemical and pharmacological actions of a putative anti-addictive drug.
Popik
P
P
Laboratory of Neuroscience, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Layer
R T
RT
Skolnick
P
P
D000818:Animals; D002118:Calcium / Q000378:metabolism; D006213:Hallucinogens / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D007050:Ibogaine / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D009498:Neurotoxins / Q000009:adverse effects / Q000633:toxicity; D018079:Receptors, GABA / Q000187:drug effects / Q000378:metabolism; D017470:Receptors, Glutamate / Q000187:drug effects / Q000378:metabolism; D011957:Receptors, Opioid / Q000187:drug effects / Q000378:metabolism; D012701:Serotonin / Q000378:metabolism; D013375:Substance Withdrawal Syndrome / Q000188:drug therapy* / Q000401:mortality; D019966:Substance-Related Disorders / Q000188:drug therapy; D009435:Synaptic Transmission / Q000187:drug effects*
D006213:Hallucinogens; D009498:Neurotoxins; D018079:Receptors, GABA; D017470:Receptors, Glutamate; D011957:Receptors, Opioid; D012701:Serotonin; D007050:Ibogaine; D002118:Calcium